Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads

Cell Cycle

Volumn 8, Issue 24, 2009, Pages 4040-4043

  Rapisarda, Annamaria ^a   Shoemaker, Robert H ^a   Melillo, Giovanni ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antiangiogenic agents; Cancer therapeutics; HIF 1; Hypoxia; Tumor microenvironment

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1 INHIBITOR; IRINOTECAN; PROTEIN INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE ARREST; CELL HYPOXIA; CELL SURVIVAL; COLON CANCER; CYTOTOXICITY; DNA DAMAGE; DNA REPLICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; EXPERIMENTAL NEOPLASM; HUMAN; LOW DRUG DOSE; LUNG SMALL CELL CANCER; METASTASIS; NONHUMAN; OVARY CANCER; RNA TRANSCRIPTION; RNA TRANSLATION; SHORT SURVEY; TUMOR XENOGRAFT;

EID: 74849127957     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.24.10145     Document Type: Short Survey

References (43)

1. Semenza GL. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 2008; 60:591-7.
2. Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 2009.
3. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 2007; 26:341-52.
4. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270:1230-7.
5. 2 tension. Proc Natl Acad Sci USA 1995; 92:5510-4.
6. Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW, et al. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005; 65:7249-58.
7. Li L, Lin X, Shoemaker AR, Albert DH, Fesik SW, Shen Y. Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo. Clin Cancer Res 2006; 12:4747-54.
8. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59:5830-5.
9. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers and tumor-associated macrophages. Am J Pathol 2000; 157:411-21.
10. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, et al. Levels of hypoxiainducible factor-1alpha during breast carcinogenesis. J Natl Cancer Inst 2001; 93:309-14.
11. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61:2911-6.
12. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60:4693-6.
13. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001; 7:1661-8.
14. Bos R, van der GP, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003; 97:1573-81.
15. Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006; 24:727-35.
16. Rapisarda A, Uranchimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res 2002; 62:4316-24.
17. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995; 182:1683-93.
18. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004; 64:1475-82.
19. Rapisarda A, Shoemaker RH, Melillo G. Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle 2004; 3:172-5.
20. Porter AC, Farr CJ. Topoisomerase II: untangling its contribution at the centromere. Chromosome Res 2004; 12:569-83.
21. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 2006; 6:789-802.
22. Hann CL, Rudin CM. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park) 2008; 22:1486-92.
23. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 2004; 64:6845-8.
24. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-39.
25. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6:273-86.
26. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005; 69:11-6.
27. Shojaei F, Ferrara N. Antiangiogenic therapy for cancer: an update. Cancer J 2007; 13:345-8.
28. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8:579-91.
29. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008; 14:6371-5.
30. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592-603.
31. Rapisarda A, Melillo G. Role of the hypoxic tumor microenvironment in the resistance to antiangiogenic therapies. Drug Resist Updat 2009; 12:74-80.
32. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-9.
33. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31.
34. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 2005; 19:7-16.
35. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
36. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3:347-61.
37. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 down-regulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003; 425:307-11.
38. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003; 198:1391-402.
39. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440:1222-6.
40. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 2009; 15:5020-5.
41. Blagosklonny MV. How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol Ther 2005; 4:1307-10.
42. Blagosklonny MV. Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int J Oncol 2001; 19:257-62.
43. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009; 8:1867-77.